Citations

Clear

6055 citation(s) found for "Wu, Peter".

Improving Documentation Quality in Oncology: Impact of a Standardized Oncology-Specific Note Template With an Embedded Structured Data Capture Form
Folstad, Matthew J, Carroll, Cibele B , Kleinschmidt, Peter , Tevaarwerk, Amye J , Emamekhoo, Hamid

Mayo Clinic

JCO Oncology Practice | November 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-26-00619 | PMID 43050645 Get It

Purpose Oncology provider notes are often lengthy, inconsistent, and incomplete, limiting clinical utility and contributing to cognitive burden. Standardized templates may improve note quality while enabling downstream real-world data use. This study evaluates the impact of a standardized, oncology-specific electronic health record (EHR) note template on documentation completeness in outpatient oncology clinics. Methods In March 2019, a template with an embedded structured data capture form was implemented to facilitate point-of-care capture of key disease- and treatment-related data elements. Data elements aligned with ASCO's Quality Oncology Practice Initiative and Minimal Common Oncology Data Elements standards. Notes were evaluated for the presence of eight predefined quality metrics (QMs) and compared based on template usage, provider template adoption patterns (regular users v nonusers), and time period. Results We reviewed 2,366 encounter notes written by 41 providers between 2018 and 2022; 917 (38.8%) used the template. Female sex, fewer years since graduation, and disease-specific clinic settings were associated with higher odds of adoption. Template use was associated with significantly greater documentation completeness across nearly all QMs. Overall completeness improved from 62.3% to 89.9% ( P < .001, Cohen d = 1.14). Cancer stage documentation increased from 62.4% to 97.8%, treatment phase from 26.2% to 92.4%, treatment intent from 40.8% to 94.8%, and performance status from 62.3% to 90.1% (all P < .001). Within-provider analyses confirmed sustained improvements for regular users; nonusers showed minimal change. Conclusion A standardized oncology-specific note template with embedded structured data capture significantly improved documentation completeness of clinically meaningful QMs in outpatient oncology clinics. Gains persisted over time and across providers, underscoring the potential of template-based documentation to enhance communication, reduce variability, and improve data quality.
Fine Particulate Matter Exposure and Sinonasal Malignant Neoplasm
Yang, Hong-Ho, Hwang, Peter H. , O’Sharkey, Karl , Grimm, David R. , Franks, Zechariah G.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | November 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaoto.2026.3453 | PMID 42986618 Get It

Importance Exposure to fine particulate matter with an aerodynamic diameter of 2.5 µm or less (PM 2.5 ) has been associated with multiple malignant neoplasms, but its relationship with sinonasal malignant neoplasm (SNM) remains poorly characterized. Objective To evaluate the association between regional PM 2.5 exposure and first observed SNM diagnosis. Design, Setting, and Participants This national case-control study used commercial outpatient claims with eligible index dates from January 2007 to December 2020. Cases were defined by the first eligible SNM diagnosis after a 1-year enrollment washout period. Controls without any SNM diagnosis throughout claims history were randomly sampled at an approximate 1:5 case to control ratio. Regional PM 2.5 exposure was derived from NASA 1-km gridded models integrating satellite, meteorologic, land-use, and atmospheric data, aggregated to each participant’s residential metropolitan statistical area and index date. Associations were evaluated using mixed-effects logistic regression with a metropolitan statistical area–level random intercept, adjusted for demographic characteristics, comorbidities, regional smoking prevalence, and socioeconomic deprivation. The analysis was conducted from March 2025 to August 2026. Exposures Mean regional PM 2.5 exposure during the 6-month, 1-year, and 5-year periods preceding the index date. Main Outcome and Measure First observed SNM diagnosis after a 1-year enrollment washout period. Results The analytic cohort included 21 295 individuals: 3600 patients with SNM (mean [SD] age, 51.5 [10.6] years; 1656 [46.0%] female and 1944 [54.0%] male participants) and 17 695 controls (41.5 [14.0] years; 9663[54.6%] female and 8032 [45.39%] male participants). Mean (SD) PM 2.5 concentrations were higher among cases than controls across the 6-month (8.57 [2.52] vs 8.36 [2.50] μg/m 3 ), 1-year (8.69 [2.45] vs 8.45 [2.43] μg/m 3 ), and 5-year (9.36 [2.67] vs 9.08 [2.67] μg/m 3 ) windows. In fully adjusted models, each SD increase in PM 2.5 was associated with higher odds of first observed SNM diagnosis (adjusted odds ratio, 1.25 [95% CI, 1.05-1.49] for 6-month average exposure, 1.31 [95% CI, 1.08-1.59] for 1-year average exposure, and 1.36 [95% CI, 1.11-1.66] for 5-year average exposure). Conclusions and Relevance In this case-control study, greater regional PM 2.5 exposure was associated with higher odds of a first observed SNM diagnosis, with larger estimates for longer averaging windows. Further epidemiologic and mechanistic investigation is warranted.
Penicillin Allergy Delabeling in Children
Larson, Anthony S. , Lim, Peter Paul , Angal, Jyoti , Perry, Tamara T. , Blumenthal, Kimberly G.

Mayo Clinic

Pediatrics | November 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1542/peds.2026-077964 | PMID 42976931 Get It

Nearly 10% of the global population has been labeled as having a penicillin allergy. Of those labeled, about 95% are not truly allergic, yet most do not receive any allergy evaluations. Patients with penicillin allergy labels are more likely to have worse clinical outcomes and incur higher health care costs, largely because they do not receive penicillin and other first-line β-lactam antibiotics for the treatment of infectious diseases. Consequently, the process of evaluating and removing inaccurate penicillin allergy labels—a process known as “delabeling”—has become increasingly supported by a growing body of evidence. Recently, penicillin allergy has garnered substantial public interest with the proposal of federal legislation to include evaluation of penicillin allergy during routine medical visits for Medicare patients. Although this moves delabeling into the generalist purview, most of the emphasis on penicillin allergies and delabeling has been on adult patients. Yet, penicillin allergy is a pressing issue for pediatrics, as most penicillin allergy labels are placed in childhood. Pediatric literature similarly demonstrates negative clinical and public health consequences of inaccurate penicillin allergy labels. Recent guidelines have strongly recommended a proactive effort to identify and delabel inaccurate penicillin allergies in children. To facilitate this process, simple delabeling procedures, such as direct oral challenge with amoxicillin, have been recommended for patients with low-risk allergy status, based on historical reaction verification, because of their safety and accuracy. These advancements are relevant to practicing pediatricians across specialties and practice locations.
Life-Course Blood Pressure Trajectories and Focal Myocardial Fibrosis in Older Age in MyoFit46
Topriceanu, Constantin-Cristian , Shiwani, Hunain , Martin, Emma , Falconer, Debbie , Bennett, Jonathan B. , Stanley, Matthew A , Gonzalez-Martin, Pablo , Tamang, Mansoon , Wong, Andrew , Pierce, Iain , Davies, Rhodri H , Lambiase, Pier D , Chaturvedi, Nishi , Kellman, Peter , Hardy, Rebecca , Moon, James C , Hughes, Alun D , Captur, Gabriella

Mayo Clinic

Hypertension | October 19, 2026 | Volume: 83 | Issue: 12 | Pages: No page available

10.1161/hypertensionaha.126.26702 | PMID 42895024 Get It

BACKGROUND: The impact of life-course blood pressure (BP) trajectories on later-life focal left ventricular (LV) fibrosis by late gadolinium enhancement (LGE) remains elusive. METHODS: MyoFit46 prospectively recruited ≈500 participants from the 1946 National Survey of Health and Development birth cohort for a cardiovascular magnetic resonance scan at 77 years, assessing LV LGE mass (in grams), calculated using the 3-SD (LGE 3SD ) or 5-SD (LGE 5SD ) methods. Cross-sectional systolic (SBPs) and diastolic BPs (DBPs) were recorded at 36, 43, 53, 63, 69, and 77 years. For each participant and age interval, annual rates of BP change (steepness) were calculated using the observed BPs, and areas under the BP trajectory curve (cumulative burden) were derived using mixed-effects models. Associations between life-course BPs and LV LGE were tested using generalized linear models, adjusted for antihypertensives, demographics, lifestyle, and comorbidities. Time-to-event associations between LV LGE and incident major adverse cardiovascular events (MACE = hospitalizations for coronary artery disease, stroke, heart failure, and atrial/ventricular arrhythmias; N=29 events) were also evaluated. RESULTS: Among 472 participants (54% were men), each 10 mm Hg increment in cross-sectional SBPs at 36 to 69 years was associated with 6% to 11% greater LV LGE 3SD (all P ≤0.033), whereas each sustained 10 mm Hg greater SBP over any age interval from 36 to 69 was associated with 16% to 24% greater LV LGE 3SD at 77 years (all P ≤0.005), with all associations independent of SBP at 77 years. Each 1 mm Hg/y steeper SBP rise during age intervals 36 to 43, 43 to 53, and 53 to 63 years was associated with 6% to 12% greater LV LGE 3SD at 77 years. Results were similar if LV LGE 5SD was used instead. Fewer associations were significant for DBPs. The qualitative presence of LV LGE was associated with greater incident MACE rates (hazard ratio, 2.5 [95% CI, 1.2–5.2]). CONCLUSIONS: Higher life-course cross-sectional BPs, greater cumulative burden, and steeper BP increases were associated with greater LV LGE burden in older age, which was linked to incident MACE. BP trajectories, beyond single-point BP measurements, warrant further investigation as tools to guide BP management strategies.
Survival disparities in primary malignant spine tumors: a national analysis of academic and community hospital care
Willis, Kameron M, Chu, Tiffany , Radwan, Hasan, Buchanan, Ian A. , Rose, Peter

Mayo Clinic

Journal of Neurosurgery: Spine | October 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.3171/2026.2.spine25907 | PMID 42887021 Get It

OBJECTIVE Primary malignant osseous tumors of the mobile spine are rare and require complex, multidisciplinary care. Treatment outcomes may differ between academic and community hospitals due to variations in resources, expertise, and infrastructure. This study evaluates demographics, care delivery patterns, and clinical outcomes, including both short- and long-term survival, for patients treated at academic versus community cancer programs using the National Cancer Database. METHODS A retrospective analysis of a prospectively maintained database was performed. Nine hundred forty-three patients diagnosed with primary malignant osseous tumors of the mobile spine between 2004 and 2017 were identified. Patients were stratified by facility type: there were 601 patients treated at academic comprehensive cancer programs (ACADs) and 342 treated at comprehensive community cancer programs (CCCPs). Demographic, treatment, and clinical data were compared using descriptive statistics. Outcomes included inpatient length of stay, time to treatment, 30- and 90-day mortality, vital status at last contact, and overall survival. A multivariable Cox proportional hazards model assessed factors associated with overall survival. RESULTS Patients at ACADs were significantly younger and more likely to have private insurance. The size and histopathological composition of the tumors did not differ significantly between facility types. ACAD patients experienced significantly longer inpatient stays and longer time to radiation initiation among patients receiving radiation with documented start dates. Time to chemotherapy did not significantly differ (p = 0.91). Thirty- and 90-day mortality were comparable between facility types among eligible surgical cases. At last follow-up, a significantly greater proportion of ACAD patients were alive (50.2% vs 38.3%, p < 0.001), and the median time from diagnosis to last contact or death was longer at ACADs (40.8 vs 33.2 months, p = 0.001). In the primary multivariable Cox model, treatment at an academic facility was associated with improved overall survival (hazard ratio [HR] 0.766, 95% CI 0.627–0.937; p = 0.009). In a sensitivity model adjusting for histopathology rather than grade, this association was attenuated and no longer statistically significant (CCCP vs ACAD, HR 1.19, p = 0.081). CONCLUSIONS Patients treated at academic centers had longer inpatient stays and longer time to radiation initiation, yet academic facility treatment was associated with improved overall survival in the primary multivariable model. After accounting for histopathological subtype in sensitivity analysis, the facility-type association was attenuated, suggesting survival differences reflect both tumor biology and system-level care pathways.
Normative transcriptomic clues to thalamic developmental vulnerability in C9orf72-FTLD
So, Isis , Bouzigues, Arabella , Ferry-Bolder, Eve , Cullen, Eva , Foster, Phoebe H , Farley, Sophie , Convery, Rhian , Jiskoot, Lize C , Seelaar, Harro , Galimberti, Daniela , Vandenberghe, Rik , Laforce, Robert , Bruffaerts, Rose , Bertoux, Maxime , Lebouvier, Thibaud , Solje, Eino , Xiong, Chengjie , Thompson, Alexander , Körtvélyessy, Peter , Otto, Markus , Uzelac, Zeljko , Illán-Gala, Ignacio , Gerhard, Alexander , Ducharme, Simon , Santana, Isabel , Masellis, Mario , Rowe, James B , Graff, Caroline , Moreno, Fermin , Synofzik, Matthis , Rademakers, Rosa , Kolander, Tyler , Boeve, Brad , Rosen, Howard J , Lee, Suzee E , Rohrer, Jonathan D , Andrews, Tallulah S , Finger, Elizabeth C.

Mayo Clinic

No container title available | October 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.10.09.26365172 | PMID 42999299 Get It

C9orf72 encodes a protein that is important for both typical neurodevelopment and homeostatic processes across the lifespan. Pathogenic C9orf72 repeat expansions constitute the most common genetic cause of frontotemporal lobar degeneration (FTLD). Collectively, preclinical models and clinical neuroimaging studies have observed smaller thalamic volumes in C9orf72-associated FTLD, including in asymptomatic young adult C9orf72 repeat expansion carriers across 18 to 30 years old, supportive of potential neurodevelopmental origins. However, it is unknown whether asymptomatic young adult C9orf72 expansion carriers demonstrate volume differences in specific thalamic nuclei, as reported in older asymptomatic carriers and symptomatic patients; if so, normative transcriptomic patterns could reveal relevant neurodevelopmental and/or FTLD-related neurodegenerative processes. This study investigated volumetric MRI differences of the thalamic nuclei in asymptomatic young adult C9orf72 expansion carriers compared to non-carriers, and examined spatial associations with normative thalamic transcriptomics from 8 weeks post-conception through middle age. Young adult C9orf72 expansion carriers (n=72) and non-carriers (n=48) were enrolled in the Frontotemporal Dementia Prevention Initiative across Europe, Canada, and the USA (ages: 18-30 years; sex: 57% female). Spatial associations between young adult thalamic nuclei volumes and normative transcriptomics from the Allen Human Brain Atlas were examined using complementary data-driven and hypothesis-driven approaches. Spatial expression patterns of transcripts of interest were characterized across prenatal and postnatal neurodevelopment using BrainSpan data. Smaller volumes of the pulvinar, mediodorsal, and lateral nuclei were observed in young adult C9orf72 expansion carriers compared to non-carriers. These nuclei showed higher normative expression of transcripts involved concurrently in neurodevelopmental and C9orf72-associated FTLD neurodegenerative processes (including lysosomal, autophagic, and small GTPase functions), and lower normative expression of CALB1, a marker of prenatal human thalamic development. Normative expression of CALB2 (another human thalamic development marker) yielded positive correlations with C9orf72 across prenatal development to adulthood. These findings identify candidate transcripts that may provide insight into the molecular architecture leading to smaller thalamic nuclei volumes in C9orf72-associated FTLD.
Serial Artificial Intelligence ECG-Derived Atrial Fibrillation Probability and Recurrence Risk After Pulsed Field Ablation
Sardana, Mayank , Rodriguez-Riascos, Juan F , Vemulapalli, Hema S , Kim, James , Attia, Zachi I , Wood, Julia , Mangold, Kathryn E , Friedman, Paul A , Noseworthy, Peter A , Srivathsan, Komandoor

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | October 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circep.126.015183 | PMID 42845233 Get It

BACKGROUND: Pulsed field ablation is now widely used for atrial fibrillation (AF) ablation, but atrial tachyarrhythmia recurrence remains common and postablation risk tools are limited. We assessed whether a validated sinus‑rhythm artificial intelligence— enabled ECG AF probability score, and its early postablation change, predicts recurrence after pulsed field ablation. METHODS: We studied consecutive patients undergoing index pulsed field ablation across 3 Mayo Clinic sites (February 2024–March 2025) with ≥1 sinus‑rhythm ECG within 180 days preprocedure. Baseline artificial intelligence—enabled ECG AF score (range 0–1) was the mean across baseline ECGs. Recovery indices (RI30/60/90), defined as mean postprocedure artificial intelligence—enabled ECG score within days 1–30/60/90 minus baseline, predicted post‑blanking recurrence using corresponding 30‑, 60‑, and 90‑day blanking windows. The primary outcome was time to first documented AF/atrial flutter/atrial tachycardia episode >30 seconds, ascertained via clinic ECGs, ambulatory monitoring, and device interrogations. Cox regression adjusted for prespecified clinical and echocardiographic covariates assessed associations; Harrell C‑statistic quantified discrimination. RESULTS: Among 1052 patients (67±10 years; 33% women), median baseline score was 0.35; 320 (30%) recurred over 188 days. Higher baseline score independently predicted recurrence (hazard ratio per 0.1 increase, 1.08 [95% CI, 1.03–1.14]). Scores rose on day 0 after ablation, then declined over subsequent weeks, with persistently higher, less‑improving trajectories among patients who recurred (time×recurrence interaction P <0.001). Day 0 score was not independently associated with recurrence after adjustment. Attenuated early recovery (higher recovery index) was independently associated with recurrence, most robustly for RI-90 (hazard ratio per 0.1 increase, 1.15 [95% CI, 1.07–1.24]), and improved discrimination beyond baseline and covariates (C‑statistic, 0.63–0.67; ΔC=0.04). Findings were consistent in a historical thermal ablation cohort. CONCLUSIONS: Baseline and early postablation dynamics of a sinus‑rhythm artificial intelligence—enabled ECG AF probability score are associated with pulsed field ablation recurrence and may aid multivariable risk stratification; prospective validation is warranted.
Risk Factors for Hypoxia, Mechanical Ventilation, and Mortality in Lung Transplant Recipients Hospitalized with Respiratory Syncytial Virus: A Multicenter International Cohort Study
Yong, Michelle K.

Mayo Clinic

Open Forum Infectious Diseases | October 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ofid/ofag623 Get It

Abstract Background Lung transplant (LT) recipients are at high risk for severe respiratory syncytial virus (RSV) infection, but predictors of worse outcomes remain poorly defined. Methods Retrospective multicenter cohort study of adult LT recipients hospitalized with PCR-confirmed RSV infection between January 2016 and December 2019. Clinical characteristics, treatments, and outcomes within 90 days were analyzed. Logistic regression was used to identify predictors of outcomes, while Cox proportional hazards models assessed risk factors for mortality. Results 155 LT recipients were included. Median age was 61 years, RSV occurred a median of 14 months post-transplant. Risk factors for hypoxic respiratory failure were baseline oxygen use [OR 4.8, (1.29–23.93)] and lower respiratory tract symptoms [OR 3.74, (1.49–10.18)]. Older age increased the risk of mechanical ventilation [OR 1.06, (1.02–1.12)], while oral ribavirin was associated with reduced risk [OR 0.34, (0.14–0.82)]; this association was attenuated when oral and inhaled ribavirin were combined into a single exposure variable [OR 0.77, (0.22–2.66)]; oral ribavirin was not associated with reduced 90-day mortality [HR 5.27, (0.68–40.83)]. Secondary bacterial or fungal infections occurred in 33.5%, associated with prior mechanical ventilation. Lung function declined significantly post-RSV infection, with nearly half experiencing &gt;10% decrease in FEV1. Ninety-day all-cause mortality was 7.7%, with mechanical ventilation independently associated with death [HR 7.79, (2.47–24.60)]. Conclusions RSV infection in LT recipients is associated with high morbidity, graft function decline, and mortality. The association between older age and severe outcomes suggests the importance of preventive strategies in this high-risk population.
NCCN Risk Groups Do Not Predict Adverse Pathology or Oncologic Outcomes Among Patients With Grade Group 1 Prostate Cancer in the MRI Era
Li, Eric V , Kim, Tae-Hee , Wang, Michael K., O'Byrne, Jamie, Shi, Chloe , Galatowitsch, Peter , Gettman, Matthew

Mayo Clinic

The Prostate | September 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/pros.70261 | PMID 42801734 Get It

ABSTRACT Background Prior studies in the pre‐MRI era suggest that patients with NCCN Intermediate and High Risk Grade Group 1 prostate cancer (GG1 PCa) on biopsy have increased risk for adverse oncologic outcomes. However, prostate MRI has altered patient selection for biopsy and improved prostate sampling. Herein, we examined factors associated with adverse pathologic features (APF) at radical prostatectomy (RP) and biochemical recurrence (BCR) among patients with GG1 in the MRI era. Methods A prospectively maintained institutional prostate cancer registry identified patients with GG1 PCa on biopsy who underwent RP from 2000 to 2023, stratified by MRI use. Multivariable logistic regression and Cox regression identified factors associated with APF at RP (GG3‐5, ≥ pT3a, or pN1) and BCR free survival (two consecutive PSA ≥ 0.2 ng/mL), respectively. Results Among patients without MRI ( n = 6732), NCCN risk group was associated with APF, BCR, and distant metastasis. Among 302 patients with GG1 and pre‐operative MRI, NCCN risk group was associated with neither APF nor BCR. Age (OR 1.07, 95% CI 1.01–1.14, p = 0.01), PIRADS ( p = 0.01), and % core positivity (OR 1.02, 95% CI 1.00–1.03, p = 0.04) were associated with APF. Age (HR 1.07, 95% CI 1.01–1.13, p = 0.03), APF (HR 4.36, 95% CI 2.14–8.86, p < 0.001), and positive margins (HR 4.88, 95% CI 2.39–9.98, p < 0.001) were associated with BCR. Conclusions Prior to prostate MRI, NCCN risk groups offered meaningful prognostication among patients with GG1 PCa. However, the utility of NCCN risk groups for GG1 in the MRI era appears limited. Contemporary risk stratification for GG1 should focus on biopsy and MRI characteristics rather than NCCN criteria.
Activation of vitamin D signaling suppresses platinum-induced ovarian cancer stem cell plasticity
Xanders, Sophie, Kinne, Renee A., Rajendran, Saranya , Zhang, Shu, Gaspar‐Maia, Alexandre , O’Hagan, Heather M. , P., Nephew Kenneth, Metcalfe, Tara X. , Kinne, Renee A., Hollenhorst, Peter C. , Nephew, Kenneth P. , Gaspar-Maia, Alexandre

Mayo Clinic

No container title available | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.22.753468 | PMID 42818011 Get It

Advanced-stage high grade serous ovarian cancer (HGSC) initially responds to platinum-based chemotherapy; however, most HGSC tumors recur and develop chemotherapy-resistance, making recurrent ovarian cancer (OC) a fatal disease. Ovarian cancer stem cells (OCSCs), a subpopulation of cells capable of surviving treatment and repopulating tumors, contribute to disease relapse, and understanding the mechanisms(s) responsible for OCSC survival is critical for developing strategies to overcome acquired resistance and prevent tumor recurrence. However, whether platinum-induced OCSC enrichment results from the selection of pre-existing OCSCs or chemotherapy-induced cellular plasticity, and the molecular mechanisms underlying these processes, remain poorly understood. Here, we demonstrated that cisplatin treatment not only enriched for OCSCs but promoted the conversion of ALDH- cells to ALDH+ cells, revealing chemotherapy-induced plasticity as a potential mechanism for OCSC expansion. This conversion was associated with nuclear receptor signaling pathways, vitamin D receptor signaling (VDR/RXR) and retinoic acid receptor signaling (RAR/RXR). Importantly, activation of VDR/RXR signaling with vitamin D reduced stemness phenotypes and the cisplatin induced conversion to ALDH+ cells. In addition, vitamin D combined with cisplatin decreased tumor volume in vivo compared to either treatment alone. In contrast, cisplatin treatment increased RAR/RXR signaling, supporting an associative role for ligand-dependent nuclear receptor signaling in OCSC plasticity. Together, these findings reveal that platinum chemotherapy can actively promote the acquisition of stem-like properties and identifies VDR/RXR signaling as a potential regulatory mechanism of OCSC plasticity. Targeting this pathway with vitamin D may provide a therapeutic strategy to target OCSCs and improve responses to platinum-based chemotherapy.